Lumican deficiency promotes pulmonary arterial remodeling

Area of Science:

• Cardiovascular Biology
• Proteoglycan Research
• Pulmonary Hypertension Pathophysiology

Background:

• Pulmonary arterial hypertension (PAH) involves extracellular matrix disorganization and increased pulmonary vascular cell proliferation.
• Lumican, a small leucine-rich proteoglycan, influences cell proliferation and TGF-β signaling.
• Reduced lumican in pulmonary arterial smooth muscle cells (PASMCs) correlates with PAH-related vascular remodeling.

Purpose of the Study:

• To investigate the role of lumican in the development of pulmonary arterial hypertension.
• To determine if lumican deficiency promotes pathological vascular remodeling in PAH.
• To evaluate the therapeutic potential of a lumican-derived peptide in reversing PAH.

Main Methods:

• Utilized rat models of monocrotaline-induced PAH and chronically hypoxic mice.
• Generated mice with homozygous deletion of lumican (Lum-/-).
• Administered a lumican C-terminal peptide (lumikine) to treat experimental PAH.

Main Results:

• Lumican-deficient mice (Lum-/-) exhibited severe pulmonary arterial remodeling and right ventricular hypertrophy under hypoxic conditions.
• Hypoxia-induced pulmonary hypertension in mice was successfully reversed by lumikine administration.
• Identified a mechanism where lumican signaling suppresses PASMC proliferation by inhibiting phosphorylated AKT activation.

Conclusions:

• Lumican deficiency exacerbates pulmonary arterial remodeling, contributing to PAH pathogenesis.
• Lumikine effectively reverses experimental PAH by targeting lumican signaling pathways.
• Lumican acts as an antiproliferative factor, suppressing pAKT activation and mitigating PAH development.